Jeffery M. Brinza J.D. is the Interim Gen. Counsel at Millendo Therapeutics.
Mr D is 58, he's been the Interim Gen. Counsel of Millendo Therapeutics since . There are 6 older and 7 younger executives at Millendo Therapeutics. The oldest executive at Millendo Therapeutics, Inc. is John Howe, 77, who is the Independent Director.
Jeffery's mailing address filed with the SEC is C/O MILLENDO THERAPEUTICS, INC., 301 N. MAIN ST., SUITE 100, ANN ARBOR, MI, 48104.
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Millendo Therapeutics executives and other stock owners filed with the SEC include: